#### 1 Incidence and risk factors associated with acquired syphilis in HIV pre-exposure

# 2 prophylaxis users

3

- 4 Nathália Lima Pedrosa<sup>1</sup>\*, Patrícia Matias Pinheiro<sup>2</sup>, Fernando Wagner Brito Hortêncio
- 5 Filho<sup>3</sup>, Wildo Navegantes de Araujo<sup>1,4,5#a</sup>

6

- 7 <sup>1</sup> Tropical Medicine Center, University of Brasília, Brasília, Federal District, Brazil
- 8 <sup>2</sup> Walter Cantídio University Hospital, Federal University of Ceará, Fortaleza, Ceará,
- 9 Brazil
- <sup>3</sup> Federal Institute of Education, Science, and Technology of Brasília, Brasília, Federal
- 11 District, Brazil
- <sup>4</sup> UnB Faculty Ceilândia, University of Brasilia, Brasília, Federal District, Brazil
- <sup>5</sup> National Institute for Science and Technology for Health Technology Assessment,
- 14 Porto Alegre, RS, Brazil

15

- <sup>#a</sup> Current Address: Postgraduate Program in Tropical Medicine, University of Brasilia,
- 17 Brasília, Federal District, Brazil

- 19 \* Corresponding author:
- 20 E-mail: <u>nati.ufc@gmail.com</u>
- 21 Phone number: +55 (61) 3107-1678
- 22 Tropical Medicine Center, University of Brasilia
  NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24	Nathália Lima Pedrosa contributed to the conception, analysis, interpretation of da	ata,
25	and drafting of the work.	

- 26 Patrícia Matias Pinheiro contributed to the conception, analysis, and interpretation of
- 27 data for the work and reviewing it critically for content.
- 28 Wildo Navegantes de Araujo contributed to the conception, analysis, and interpretation
- 29 of data for the work and reviewing it critically for content.
- 30 Fernando Wagner Brito Hortêncio Filho contributed to analyzing and interpreting data
- 31 for the work and reviewing it critically for content.
- 32 All the authors approved the final version of this article, agree to all aspects of this
- 33 work, and declare that there are no competing interests.

#### 34 Abstract

**Background:** Acquired syphilis continues to affect millions of people around the world. It is crucial to study it in the context of HIV Pre-Exposure Prophylaxis (PrEP) to achieve the goals set out in the 2030 Agenda since the literature suggests increased risk behaviors for sexually transmitted infections. This study aimed to investigate the incidence and factors associated with acquired syphilis among PrEP users.

40 Materials and methods: This retrospective cohort included data on PrEP users from all 41 over Brazil from 2018 to 2020, obtained from the national antiretroviral logistics 42 system. We calculated the proportion of syphilis before PrEP, the incidence during the 43 user's follow-up, reinfections, and their possible associated factors. We conducted 44 descriptive, bivariate, and multivariate analysis, estimating the crude Relative Risk, 45 adjusted Odds Ratio (aOR), and their respective confidence intervals (95%CI).

46 **Results:** Most of the 34,000 individuals who started PrEP were male (89.0%), white (53.7%), self-identified as male (85.2%), homosexual, gay, or lesbian (72.2%), and had 47 12 schooling years or more (67.8%). Of these, 8.3% had syphilis in the six months 48 before starting PrEP, and 4% had it in the first 30 days of using the prophylaxis. In the 49 19,820 individuals effectively monitored, the incidence of acquired syphilis was 19.1 50 cases per 100 person-years, and 1.9% of users had reinfection. The multivariate analysis 51 identified female gender (aOR 0.3; 95%CI 0.2-0.5), being white or Black (aOR 0.9; 52 95%CI 0.7-0.9 and aOR 0.7; 95%CI 0.7-0.99, respectively) as protective factors for 53 syphilis. Being homosexual, gay, lesbian (aOR 2.7; 95%CI 2.0-3.7) or having a history 54 55 of syphilis in the six months before PrEP (aOR 2.2; 95%CI 1.9-2.5) were risk factors for syphilis during PrEP use. Behaviors related to the risk of syphilis included accepting 56 something in exchange for sex (aOR 1.6; 95%CI 1.3-1.9), irregular condom use (use in 57

- less than half of sexual intercourse sessions; aOR 1.7; 95%CI 1.53-2.1) and recreational
- 59 drug use (poppers; aOR 1.5; 95%CI 1.53-2.1).
- 60 Conclusion: Syphilis in the context of PrEP has high rates and is associated with
- 61 sociodemographic and behavioral factors. We recommend additional studies targeting
- 62 prevention in this population to curb these figures.
- 63 **Keywords:** Syphilis; HIV; PrEP; Cohort; Brazil.

# 64 INTRODUCTION

Acquired syphilis is the most common sexually transmitted infection (STI) worldwide. Although it has been recognized since the 15<sup>th</sup> century, it continues to represent a contemporary challenge, affecting millions of people, with an annual estimate of 7.1 million (3.8-10.3 million) new infections between 2016 and 2020 worldwide [1-3].

Syphilis is caused by the spirochete bacterium Treponema pallidum. It can 70 result in severe health complications and genital symptoms, including complications 71 72 during pregnancy, infertility, increased risk of infection by the human immunodeficiency virus (HIV), and psychological impacts if not appropriately treated. 73 74 The incidence is significantly higher in men who have sex with men (MSM) and in 75 people living with HIV (PLHIV). Appropriate management involves staging the disease, treatment with benzathine penicillin for the individual and their partners, 76 77 screening in at-risk populations, and notification to health authorities to support control 78 and prevention [2-5].

In response to this enduring public health issue, syphilis has been incorporated
into the Sustainable Development Goals of Agenda 2030, launched by the United
Nations (UN), and the Strategic Guidelines for the Elimination of Sexually Transmitted
Infections by the World Health Organization (WHO), which aim to reduce the incidence
of *T. pallidum* infections by 90% [1].

Besides this setting, Pre-Exposure Prophylaxis (PrEP) has emerged as a crucial strategy in the fight against HIV. Launched in 2012 and widely disseminated globally, the provenly highly effective PrEP involves the use of oral antiretrovirals (ARVs) (in daily doses or on-demand) to reduce the risk of infection by the virus [6]. While PrEP has reduced HIV worldwide, the low use of condoms in individuals using prophylaxis

and other "risk compensations" [7] may pose additional challenges in reducing syphilisand achieving the goals set for the 2030 Agenda.

Despite the extensive research on PrEP and STIs, there is a dearth of studies analyzing acquired syphilis, its recurrence among PrEP users, and the factors associated with its incidence. These findings could provide critical evidence to strengthen strategies to combat syphilis and help achieve the targets set by the WHO. Therefore, this study aimed to analyze the incidence of acquired syphilis in the population of PrEP users and identify the factors associated with this incidence.

### 97 MATERIALS AND METHODS

## 98 Design

99 This retrospective cohort employed secondary longitudinal data from the 100 Brazilian Ministry of Health's Medicines Logistics Control System (SICLOM), which 101 is used nationwide to manage the distribution of antiretroviral drugs. This system keeps 102 records of ARV users, both for treatment and prophylaxis, along with clinical and 103 laboratory information on the follow-up of these users [8].

The databases extracted from SICLOM, containing information from 104 105 standardized appointments with PrEP users, were provided by the Ministry of Health 106 after the study was approved by the Ethics Committee of the Faculty of Medicine of the 107 University of Brasília (CAAE: 07448818.0.1001.5558). The data was made available to researchers on March 7, 2021 and were anonymized by removing names, dates of birth, 108 109 and addresses before being made available to the researchers and replaced by untraceable numerical codes for each study participant in order to guarantee information 110 111 confidentiality and the protection of PrEP users.

During the period in which the database was available (2018-2020) in 112 113 Brazil, the guidelines standardized care for PrEP users, recommending an initial appointment to collect sociodemographic and behavioral risk data and clinical and 114 115 laboratory investigation for HIV and other sexually transmitted infections (STIs), using specific forms (Supplement 1). After the first return in 30 days, PrEP users should be 116 followed up every three months for clinical and laboratory follow-up [9]. During the 117 118 study period, the Unified Health System performed evaluation and follow-up appointments, laboratory tests, and the dispensing of antiretroviral drugs for PrEP at no 119 cost to the user [10]. 120

121 A database was compiled for each form used between 2018 and 2020. The 122 process of qualifying the database of PrEP users is described in Supplement 2. It 123 allowed for following the PrEP user's trajectory from admission to the last available 124 follow-up appointment.

#### 125 Study population

Considering the target study population as PrEP users, we selected individuals who met the eligibility criteria in the national policy in force at the time [9] for prophylaxis in Brazil, seen between January 2018 and December 2020 and who had at least one follow-up visit. Afterward, users for whom it was impossible to obtain information from any subsequent forms were excluded through a deterministic relationship between the different databases created from the records derived from the completed forms (Supplement 2).

In Brazil, the PrEP eligibility criteria include sexually active people with increased risk for HIV, such as sexual practices with penetration without the use of condoms, multiple casual sexual partners, diversity and frequency of sexual

partnerships, history of STIs, repeated search for HIV Post-Exposure Prophylaxis
(PEP), sexual relationships in exchange for money or material goods, and Chemsex
(sexual practice under the influence of psychoactive drugs).

While not exclusive, serodiscordant couples and primary populations (gay men, men who have sex with men (MSM), transgender people, and sex workers) should be given preference in the provision of PrEP by the Unified Health System (SUS) [9].

#### 142 Measures

143 Data collected consisted of sociodemographic characteristics (genitalia at birth, self-reported ethnicity/skin color, gender identity, sexual orientation, age, and 144 schooling years), behavioral characteristics in the last three months (sex in exchange for 145 146 money/goods, condom use frequency, alcohol consumption, use of injectable drugs and other psychoactive drugs, number and type of sexual partnerships), and health 147 148 characteristics (history of STIs in the last six months and presence of active syphilis during follow-up). Self-reported ethnicity/skin color is used per the Brazilian Institute 149 of Geography and Statistics (IBGE). We arbitrated the information referring to the last 150 151 appointment for follow-up behavioral data.

In Brazil, the diagnosis of syphilis is guided by clinical evaluation and direct (when with symptoms) or immunological (regardless of symptoms) tests. Concerning the latter, which are more common in routine services, guidelines recommend starting the investigation with a treponemal test (preferably a rapid test) followed by a nontreponemal test (VDRL or RPR) when the first test is positive [11]. The history of acquired syphilis was assessed in the six months before the first appointment through the report of diagnosis or the syphilis serological screening on admission.

In this cohort, the duration of follow-up for PrEP users was calculated as the time elapsed between the date of the first visit and the date of the last follow-up visit, regardless of adherence. Moreover, users who did not attend at least one follow-up appointment were considered losses in the cohort and compared with those who did follow up regarding schooling, ethnicity/skin color, and sexual orientation to check for differences between the groups.

The incidence of acquired syphilis during PrEP use was measured by the 165 166 number of "active syphilis" events identified by health professionals after three months of prophylaxis use, obtained from the data on the Monitoring Form, following the 167 method described by Ong [12]. The outcome could also be observed on more than one 168 occasion during the user's follow-up, and this event was defined as a syphilis 169 170 reinfection outcome during PrEP follow-up and calculated as another incident event. 171 We could, thus, measure the proportion of users who acquired syphilis at least twice or 172 more during PrEP.

# 173 Statistics

We presented the continuous variables (age and number of sexual partners) using measures of central tendency (mean and median) and dispersion (standard deviation and interquartile range), and the categorical variables were described using measures of absolute and relative frequency in each category. The individual's time in the cohort was calculated as the difference between the date of registration in the system (when PrEP started) and the date of the last appointment recorded in the system. The user follow-up period and syphilis incidence were calculated per 100 person-years.

181 Sociodemographic and behavioral variables were compared between182 individuals diagnosed with syphilis and those who were not diagnosed during follow-

183 up. Subsequently, the bivariate association between the outcome and the covariates was 184 verified using the chi-square or Fisher's exact test for categorical variables and the 185 Wilcoxon test for numerical variables, considering the difference statistically significant 186 if p < 0.05. Furthermore, we calculated the Relative Risk (RR) and the 95% Confidence 187 Interval (95% CI) to evaluate the possible factors associated with syphilis infection 188 during PrEP use.

We then carried out a logistic regression analysis using the backward-stepwise 189 190 method to control for confounders. In this regression, we considered active syphilis during PrEP (yes or no) as the dependent variable and the sociodemographic, 191 behavioral, and sexual health variables whose bivariate analysis showed a p-value < 0.2192 193 as independent variables. We assessed multicollinearity using Variance Inflation Factors 194 (VIF) and identified the best model using the Akaike Information Criterion (AIC) and pseudo R<sup>2</sup>. Considering the low risk of the outcome in this study, we estimated the 195 196 Relative Risk adjusted by the adjusted odds ratio (aOR) and its Confidence Intervals (95% CI) to assess the effect of the adjusted covariates on the outcome. 197

The above analyses were performed using the R® 4.3.3 software using the libraries tidyverse, janitor, stringr, rio, here, purrr, gtsummary, broom, lmtest, parameters, see, readxl, plyr, with code provided as supplementary material (Supplement 2).

202 **RESULTS** 

After linking the databases of PrEP consultation forms, we obtained 34,000 records of people who started using PrEP and 19,820 users who followed up and were part of the cohort. The base population of this cohort reflects PrEP users in Brazil between 2018 and 2020, as shown in Table 1. Most PrEP users were male (89.0%),

white (53.7%), self-identified as male (85.2%), were homosexuals, gays, or lesbians (72.2%), and had 12 years or more of schooling (67.8%) (Table 1).

209 **Table1** 

In total, 19,820 people were effectively followed up, with a median followup of seven months (IQR=7-20 months). We observed a loss-to-follow-up rate of 41.7% among those who started PrEP. Similar to the initial cohort, most were men (86%), homosexuals, gays, or lesbians (67%), white (51%), and had 12 years or more of schooling (61%), with p < 0.001.

Table 2 shows an overview of acquired syphilis among PrEP users. During the initial appointment, 8.3% of individuals reported a history of acquired syphilis, and 4.0% of those who returned for follow-up after 30 days were diagnosed with active syphilis.

219 Table 2

In this cohort, 1,962 individuals (9.8%) received at least one diagnosis of active syphilis during follow-up, and 2% of users had a recurring infection, i.e., more than one episode of syphilis during follow-up. In total, 2,525 diagnoses of active syphilis were recorded, resulting in an incidence of 19.1 cases of acquired syphilis per 100 person-years (95% CI 18.4-19.9). There was a high proportion of missed syphilis tests in the 30-day return period (33.4%) and the total number of follow-up appointments (38.8%).

To analyze the risk factors associated with acquired syphilis, we compared individual and behavioral characteristics between people with at least one diagnosis of acquired syphilis during follow-up and PrEP users who did not receive such a diagnosis during the period (see Table 3).

#### 231 **Table 3**

In the bivariate analysis, statistically significant differences were observed in the following variables: sex at birth, sexual orientation, gender identity (transgender), ethnicity/skin color, schooling years (4-7 years and 12 years or more), having accepted something in exchange for sex, history of previous syphilis in the last six months, frequency of condom use in the last three months, number of sexual partners in the last three months, and alcohol and other psychoactive drugs abuse in the last three months.

The multivariate analysis (see Table 3) identified no multicollinearity based on VIF (see Supplement 2). After we identified the most parsimonious model, the variables independently associated with the incidence of syphilis in the cohort were age, sex at birth, self-reported ethnicity/skin color, having accepted something in exchange for sex, history of previous syphilis in the last six months, frequency of condom use in the last three months, number of sexual partners in the last three months (men, women, and transsexuals) and use of poppers, cocaine, marijuana, and erection stimulants.

Regarding the risk of acquired syphilis during PrEP use, being a woman was a protective factor (aOR 0.3; 95% CI 0.2-0.5). White and Black people had an 80% lower risk of having syphilis than brown people (95% CI 0.7-0.9 and 0.7-0.99, respectively). Homosexuals, gays, and lesbians were 2.7 times (95% CI 2.0-3.7) more likely to be at risk of having syphilis than heterosexuals. Moreover, individuals with a history of syphilis in the six months before PrEP were 2.2 times (95% CI 1.9-2.5) more likely to be at risk of acquiring syphilis during follow-up.

Regarding behaviors reported at the last follow-up visit, people who accepted something in exchange for sex were 1.6 times (95% CI 1.3-1.9) more likely to be at risk of having syphilis than individuals who did not engage in this practice. Irregular condom use increased by at least 1.2 times the risk compared to those who use condoms

in all relationships. The use of recreational drugs such as poppers (aOR 1.5; 95% CI 1.2-1.9), cocaine (aOR 1.5; 95% CI 1.2-1.7), and marijuana (aOR 1.2; 95% CI 1.01-1.3)
is also associated with an increased risk of syphilis during PrEP use. There was also a
difference between the groups regarding age and the number of male sexual partners.

#### 260 **DISCUSSION**

This research analyzed a cohort using digital records from different stages 261 among PrEP users nationwide to understand the incidence of syphilis in the context of 262 PrEP and its associated factors. Most PrEP users were male, white, self-identified as 263 264 male, homosexual, gay or lesbian, and had 12 or more schooling years. Our findings revealed a prevalence of 8.3% of syphilis in the six months before starting PrEP, 4% in 265 the first 30 days of prophylaxis use, and 9.8% of all those followed up in this cohort had 266 syphilis during follow-up (with an incidence of 19.1 cases of acquired syphilis per 100 267 people), with 1.9% reinfected users. 268

269 The multivariate analysis identified female gender as a protective factor 270 against syphilis during PrEP, as with being white or Black. On the other hand, the main 271 risk factors for syphilis during PrEP were identified as being homosexual, gay, or lesbian and having a history of syphilis in the six months before starting PrEP. Risk 272 273 behaviors associated with syphilis included accepting something in exchange for sex, 274 irregular condom use, and recreational drug use. We also observed significant differences between the groups regarding age and the number of male sexual partners. 275 Moreover, we noted a significant proportion of follow-up appointments without testing 276 277 or with unavailable tests.

Our findings estimated an 8.3% prevalence of syphilis in the six months before starting PrEP. Recent studies of PrEP users in other countries have revealed rates of 10.1% (95% CI 7.6-13.1%) in Canada [13], 3.63% (95% CI 2.93-4.44%) in Germany

[14] and 25.8% in France [15]. However, it is essential to exercise caution when
comparing these studies since the approach to analyzing the history of syphilis before
PrEP can vary (interview, history of laboratory tests, and medical records), which can
directly influence the prevalence estimates found.

The follow-up of PrEP users in Brazil revealed an incidence of 19.1 cases of 285 acquired syphilis per 100 person-years (95% CI 18.4-19.9). This incidence can be 286 considered relatively high against results from other cohorts of PrEP users in Australia 287 288 (9.4 (9.0-9.8) /100 PA) [16], Canada (1.94 (0.73-5.12) /100 BP) [13], and the United States (7.8 (7.1-8.4) /100 BP) [17], but similar to findings in Denmark (21.7 /100 BP) 289 [18] and Spain (15.99 (11.94-21.41) /100PA) [19]. These regional disparities need to be 290 291 better investigated. They may reflect vulnerabilities arising from the response of the 292 countries' public policies in the fight against syphilis and the profile of PrEP users in each country. 293

While our findings found 1.9% reinfection, Lemmet et al [15] showed 17.1% of PrEP users followed up in France with reinfection, mainly in older people (aOR 1.31; 95% CI 1.04-1.67) and MSM (aOR 2.71; 95% CI 1.89-3.96). However, syphilis reinfection in the context of PrEP is little explored in the studies. It is, therefore, recommended to explore the factors associated with syphilis reinfection in further studies. Our low rate can be explained by the low testing level detected during followup appointments, perhaps due to fewer referrals to primary care.

Regarding the factors associated with syphilis in the PrEP, the study by Lemmet et al [15] corroborates our findings, as it shows that female gender can be a protective factor, while people with syphilis in PrEP may be 6.6 more likely (CI 95% 5.10-8.66) to be men who have sex with men. Our findings also showed female gender as a protective factor, being homosexual, gay, or lesbian, and age as a risk factor. A

306 study conducted by Peel et al [20] in Australia showed that PrEP users diagnosed with 307 syphilis had a mean of 33 years and that, as in our findings, there is evidence that a 308 syphilis history is a relevant risk factor [14, 15].

Regarding behaviors associated with syphilis infection during PrEP, our study 309 310 found a significant association between recreational drug use and syphilis acquired during PrEP, particularly for poppers, marijuana, cocaine, and erection stimulants. One 311 312 study identified that sexual drugs and chemsex have a significant association with the 313 number of partners, search for partners on the internet, and low condom use with casual partners [21]. These findings may corroborate an increased vulnerability with the use of 314 315 these substances. Hetcher et al [17] emphasizes that the relationship between the use of 316 these substances and STIs needs to be examined more directly in order to understand 317 the mechanisms that promote the vulnerability of individuals when they are using these 318 substances. Indeed, understanding how these fragilities operate in the health-disease 319 process for syphilis can facilitate management during PrEP to prevent this infection and 320 other STIs.

321 Although the highest proportion of PrEP users are white (53.7%), this category of the ethnicity/skin color variable has an 80% lower risk of syphilis infection than 322 323 brown people. In the Brazilian population, most people self-declare brown (45.3%) or white (43.5%) [22], and this can be investigated in future studies in light of the unequal 324 325 access to PrEP in Brazil. In Brazil, equitable access by law to health resources through 326 the health decentralization policy of the Unified Health System has significant challenges, considering that it offers a universal system to more than 180 million 327 inhabitants. The unequal distribution of health resources is a persistent reality in several 328 329 contexts and is a complex issue [23]. However, the possible unequal distribution of PrEP would occur not only in Brazil but also among Americans [24]. 330

Furthermore, we observed significant follow-up appointments without testing 331 332 or unavailable tests. The COVID-19 pandemic may have impacted the quality of care involving serological testing [25], which started in 2020 since the provision of services 333 during this period was adversely affected, with outpatient sexual and reproductive 334 health services adopting models of care that avoided face-to-face appointments and 335 336 hospitals with shortened appointments in order to reduce the number of people in 337 hospital environments. Moreover, people from the lesbian, gay, bisexual, transgender, queer, intersex, and agender (LGBTQIA+) community, a primary population for PrEP, 338 339 can face barriers in health services due to misgendering, stigma, and attitudes that can 340 generate bad experiences for them, interfering with their healthcare [26]. Individual service and social issues, such as improving the convenience of testing through self-341 342 testing and offering a service that men feel comfortable and safe accessing, should be 343 considered by health services to make STI testing more accessible to MSM [27]. Serological testing for both syphilis and other STIs is a relatively simple and low-cost 344 345 technology in the care of PrEP users. It should be prioritized in the context of inputs for 346 primary health services.

Differentiated approaches to syphilis should be considered for this specific 347 subgroup of PreP users. Initially, we could not observe in this Brazilian research an 348 349 approach to communication with sexual partners for testing and treatment in order to interrupt the chain of transmission of syphilis, although recommendations are in place in 350 this country and elsewhere in the world [9, 28]. Also, the use of social media apps for 351 sexual encounters can favor anonymity and an increase in the number of partners [29]. 352 However, this variable may not be addressed during follow-up appointments as it is not 353 354 included in the guide form for monitoring appointments. It is, therefore, recommended to explore new approaches within PrEP to reduce STIs. 355

Our study has some limitations. Firstly, the proportion of losses in the cohort 356 357 was high (41%). However, the individual characteristics of those lost to follow-up were 358 similar, proportionally, to those who continued (homosexuals, whites, and with a high schooling level). Secondly, the behavioral variables during follow-up were extracted 359 only from the last visit, which may not have captured changes during PrEP use and the 360 361 possible influence of these changes on Treponema pallidum infection. We recommend 362 studies that analyze the behavior of PrEP users over time. Thirdly, some data were not recorded at the last visit, which can introduce information bias, and a significant 363 364 proportion of tests was not run on appointments, which can underestimate the actual 365 incidence density of acquired syphilis. Finally, as the data were obtained through interviews conducted by health professionals, there may have been inhibition in 366 367 responses and underestimation of behaviors due to social desirability. Given the users' 368 schooling level, we should consider using self-administered questionnaires to reduce this bias. 369

These limitations underscore the need for caution in interpreting the results and 370 highlight areas for future research aimed at improving understanding of the factors 371 372 associated with syphilis in PrEP users and improving the quality of the data collected during follow-up of these individuals. Despite the limitations, our study provides 373 substantial evidence for understanding syphilis during HIV prophylaxis. Besides the 374 high rates of acquired syphilis, the findings related to associated factors can contribute 375 to developing specific public policies geared to the health of homosexual men, those 376 with a history of syphilis, a high number of sexual partnerships, and recreational drug 377 users, curbing syphilis transmission rates and achieving the 2030 Agenda global goals. 378

We should underscore that the high incidence of syphilis among PrEP users should not be seen as a disadvantage of this form of prophylaxis, which could lead to

compensatory risk behaviors. This situation requires additional studies beyond secondary data to explore other associated factors. Thus, the detection of syphilis and other STIs should be an integral part of managing these users during follow-up, and PrEP is an essential policy for reducing STI rates.

# 385 **References**

- 1. Almeida MCD, Cordeiro AMR, Cunha-Oliveira A, Barros DMS, Santos DGSM,
- Lima TS, et al. Syphilis response policies and their assessments: A scoping review.
- 388 Front Public Health. 2022; 16(10):1002245. doi: 10.3389/fpubh.2022.1002245.
- 2. Forrestel AK, Kovarik CL, Katz KA. Sexually acquired syphilis: Historical aspects,
- microbiology, epidemiology, and clinical manifestations. J Am Acad Dermatol. 2020;
- 391 82(1):1-14. doi: 10.1016/j.jaad.2019.02.073. Epub 2019 Apr 12. PMID: 30986477.
- 392 3. Tudor ME, Al Aboud AM, Leslie SW, Gossman W. Syphilis [Updated 2023 May
- 30]. Treasure Island (FL): StatPearls Publishing; [Cited 2024 March 29]. Available
- from: Available from: <u>https://www.ncbi.nlm.nih.gov/books/NBK534780/</u>
- 4. Forrestel AK, Kovarik CL, Katz KA. Sexually acquired syphilis: Laboratory
- diagnosis, management, and prevention. J Am Acad Dermatol. 2020; 82(1):17-28. doi:
- 397 10.1016/j.jaad.2019.02.074. PMID: 30986474.
- 5. Pan American Health Organization. Sexually Transmitted Infections 2024 [Cited
- 399 2024 March 29]. Available from: <u>https://www.paho.org/en/topics/sexually-transmitted-</u>
- 400 <u>infections</u>
- 401 6. Lazarus G, Wangsaputra VK, Christianto, Louisa M, Soetikno V, Hamers RL. Safety
- 402 and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1
- 403 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized
- 404 Trials. Front Pharmacol. 2021;12:664875. doi: 10.3389/fphar.2021.664875. PMID:
- 405 34305587; PMCID: PMC8299834.

- 406 7. Cannon C, Celum C. Sexually transmissible infection incidence in men who have sex
- 407 with men using HIV pre-exposure prophylaxis in Australia. Lancet Infect Dis. 2022
- 408 ;22(8):1103-1105. doi: 10.1016/S1473-3099(22)00284-5. Epub 2022 May 25. PMID:
- 409 35643091.
- 410 8. Ministry of Health of Brazil. Sistema de Controle Logístico de Medicamentos
- 411 (Siclom) [Updated 2023 July 23]. Brasília: Ministério da Saúde. [Cited 2024 March 25].
- 412 Available from: <u>https://www.gov.br/aids/pt-br/sistemas-de-informacao/siclom</u>
- 413 9. Ministério da Saúde. Protocolo Clínico de Diretrizes Terapêuticas para Profilaxia
- 414 Pré-exposição para HIV. 2018 [Cited 2024 March 20]. Available from:
- 415 <u>http://www.aids.gov.br/publicacao/2017/protocolo-clinico-e-diretrizes-terapeuticas-</u>
- 416 para-profilaxia-pre-exposicao-prep-de-ri
- 417 10. Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The Brazilian health system:
- 418 history, advances, and challenges. Lancet. 2011;377(9779):1778-1797.
- 419 doi:10.1016/S0140-6736(11)60054-8
- 420 11. Ministry of Health of Brazil. Protocolo Clínico de Diretrizes Terapêuticas para
- 421 Profilaxia Pré-exposição para HIV. 2022 [Cited 2024 March 20]. Available from:
- 422 https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts/2017/hiv-aids/pcdt-prep-
- 423 versao-eletronica-22\_09\_2022.pdf/view
- 424 12. Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, Rafael S, et al. Global
- 425 Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals
- 426 Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic
- 427 Review and Meta-analysis. JAMA Netw Open. 2019; 2(12):e1917134. doi:
- 428 10.1001/jamanetworkopen.2019.17134. PMID: 31825501; PMCID: PMC6991203.
- 429 13. Candler E, Naeem Khan M, Gratrix J, Plitt S, Stadnyk M, Smyczek P, et al.
- 430 Retrospective audit of a convenience cohort of individuals on HIV pre-exposure

- 431 prophylaxis in Alberta, Canada. J Assoc Med Microbiol Infect Dis Can. 2022; 7(4):350-
- 432 363. doi: 10.3138/jammi-2022-0016. PMID: 37397818; PMCID: PMC10312220.
- 433 14.Schmidt D, Kollan C, Bartmeyer B, et al. Low incidence of HIV infection and
- decreasing incidence of sexually transmitted infections among PrEP users in 2020 in
- 435 Germany. Infection. 2023; 51(3):665-678. doi:10.1007/s15010-022-01919-3
- 436 15. Lemmet T, Cotte L, Allavena C, et al. High syphilis prevalence and incidence in
- 437 people living with HIV and Preexposure Prophylaxis users: A retrospective review in
- 438 the French Dat'AIDS cohort. PLoS One. 2022; 17(5):e0268670.
- 439 doi:10.1371/journal.pone.0268670
- 440 16. Traeger MW, Murphy D, Ryan KE, et al. Latent Class Analysis of Sexual
- 441 Behaviours and Attitudes to Sexually Transmitted Infections Among Gay and Bisexual
- 442 Men Using PrEP. AIDS Behav. 2022; 26(6):1808-1820. doi:10.1007/s10461-021-
- 443 03529-w
- 444 17. Hechter RC, Bruxvoort KJ, Zhou H, et al. Sexually transmitted Infections Among
- 445 Men and Transgender Women Using HIV Pre-exposure Prophylaxis in a Large
- 446 Integrated Health System-A Cohort Study. J Acquir Immune Defic Syndr. 2022;
- 447 91(1):1-8. doi:10.1097/QAI.000000000003015
- 448 18. Azarnoosh M, Johansen IS, Martin-Iguacel R. Incidence of Sexually Transmitted
- 449 Infections After Initiating HIV Pre-Exposure Prophylaxis Among MSM in Southern
- 450 Denmark. Am J Mens Health. 2021; 15(3):15579883211018917.
- 451 doi:10.1177/15579883211018917
- 452 19. Iniesta C, Coll P, Barberá MJ, et al. Implementation of pre-exposure prophylaxis
- 453 programme in Spain. Feasibility of four different delivery models. PLoS One.
- 454 2021;16(2):e0246129. doi:10.1371/journal.pone.0246129

- 455 20. Peel J, Chow EPF, Denham I, et al. Clinical Presentation of Incident Syphilis
- 456 Among Men Who Have Sex with Men Taking HIV Pre-Exposure Prophylaxis in
- 457 Melbourne, Australia. Clin Infect Dis. 2021; 73(4):e934-e937. doi:10.1093/cid/ciab052
- 458 21. Giacalone S, Barberi F, Ramoni S, Casazza G, Cusini M, Marzano AV. Sexualised
- 459 drug use and chemsex in Italy: A questionnaire study based on a cohort of clients
- attending a STI outpatient service in Milan. Int J STD AIDS. 2023; 34(14):1034-1041.
- 461 doi: 10.1177/09564624231193055. PMID: 37608639.
- 462 22. Brazilian Institute of Geography and Statistics. Censo 2022. [Cited 2024 April 04].
- 463 Available from: <u>https://censo2022.ibge.gov.br/panorama/</u>
- 464 23. Mello GA, Pereira APCM, Uchimura LYT, Iozzi FL, Demarzo MMP, Viana ALD.
- 465 A systematic review of the process of regionalization of Brazil's Unified Health System,
- 466 SUS. Cien Saude Colet. 2017; 22(4):1291-1310. doi: 10.1590/1413-
- 467 81232017224.26522016. PMID: 28444053.
- 468 24. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. HIV
- 469 prevention pill not reaching most Americans who could benefit especially people of
- 470 color. 2018. [Cited 2024 April 04]. Available from:
- 471 <u>https://www.cdc.gov/nchhstp/newsroom/2018/croi-2018-PrEP-press-release.html</u>
- 472 25. Tam MW, Davis VH, Ahluwalia M, Lee RS, Ross LE. Impact of COVID-19 on
- 473 access to and delivery of sexual and reproductive healthcare services in countries with
- 474 universal healthcare systems: A systematic review. PLoS ONE. 2024; 19(2): e0294744.
- 475 https://doi.org/10.1371/journal.pone.0294744
- 476 26. Ford, L. G., Lewis, C., & Volberding, J. L. The Perceptions and Experiences
- 477 Among Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, and Agender Patients of
- 478 Quality of Care With Health Care Services. International Journal of Athletic Therapy
- 479 and Training. 2024. doi:10.1123/ijatt.2022-0140

- 480 27. Kularadhan V, Gan J, Chow EPF, Fairley CK, Ong JJ. HIV and STI Testing
- 481 Preferences for Men Who Have Sex with Men in High-Income Countries: A Scoping
- 482 Review. Int J Environ Res Public Health. 2022; 19(5):3002. doi:
- 483 10.3390/ijerph19053002. PMID: 35270694; PMCID: PMC8910668.
- 484 28. Republic of Uganda Ministry of Health. Assisted Partner Notification Training for
- 485 Providers in Clinical Settings. Uganda, Kampala: 2018. [Cited 2024 Abril 02]
- 486 Available from: <u>https://nastad.org/sites/default/files/2021-12/PDF-Assisted-Partner-</u>
- 487 <u>Notification-Training.pdf</u>
- 488 29. Ghanem KG, Ram S, Rice PA. The Modern Epidemic of Syphilis. N Engl J Med.
- 489 2020; 382(9):845–54. https://doi.org/10.1056/NEJMra1901593

# 491

# Table 1. Demographic characteristics of PrEP<sup>1</sup> users for HIV in Brazil (2018-2020).

Variables (n)	n (%)
Sex at birth(34,000)	
Male	30,208 (89.0)
Female	3,771 (11.0)
Hermaphrodite	21 (<0.1)
Self-reported ethnicity/skin color (33,990)	
White	18,252 (53.7)
Pardo (Brown, i.e., mixed race)	10,945 (32.2)
Black	4,290 (12,6)
Yellow (i.e., Asian Brazilian)	359 (1.0)
Indigenous	144 (0.4)
Gender identity (34,000)	
Man	28,956 (85.2)
Transgender man	103 (0.3)
Woman	3,970 (12)
Transgender woman	790 (2.3)
Transvestite	181 (0.5)
Sexual Orientation (34,000)	
Bisexual	3,351 (9.9)
Heterosexual	6,092 (17.9)
Homosexual, gay, or lesbian	24,557 (72.2)
Schooling level <sup>2</sup> (33,991)	
1-3 years	193 (0.6)
4-7 years	1,616 (4.8)
8-11 years	9,071 (26.7)
12 years and over	23,040 (67.8)
None, no formal education	71 (0.2)

<sup>494</sup> 495

496

....

498

# Table 2. Characterization of acquired syphilis before and during followup in HIV PrEP users, Brazil, 2018-2020.

Variables					n (%)
Syphilis within 6 m appointment <sup>1</sup> (34,000*)	onths befo	re the	initial	PrEP	2,806 (8.3)
Active syphilis on appointment (19,440**	return 30 )	days	after	initial	
Yes					775 (4.0)
No					12,174 (62.6)
Not performed/unavailal	ole				6,491 (33.4)
Active syphilis during	HIV PrEP (1	19,820**	)		
Yes					1,962 (9.8)
No					17,858 (90.1)
Active syphilis per folle	ow-up appoi	ntment (	(79,753*	***)	
Yes					2,525 (3.2)
No					46,222 (58.0)
Not performed/unavaila	ole				30,949 (38.8)
Number of active syph	ilis episodes	per user	· (19,820	)**)	
0					17,858 (90.1)
1					1,590 (8)
2					290 (1.5)
3					65 (0.3)
4					15 (<0.1)
5					2 (<0.1)
* Study base population made. <sup>1</sup> PrEP = Pre Expo	on; ** Coho sure Prophyla	rt popul axis.	ation; *	** Tota	l follow-up appointment

Variable (n)	Syphilis episode during PrEP		RR*	95% CI	p-value ***	aOR <sup>#</sup>	95%CI##	p-value ***
	Yes n (%)	No n (%)						
	(n=1,962)	(n=17,858)						
Age (19,811)	32 ± 8 (31)**	33 ± 9 (31)**			0.366			< 0.001
Sex at birth (19,810)								
Man	1,934 (98.6)	16,113(90.3)	1			1		
Woman	27 (1.4)	1,736 (9.7)	0.15	0.1-0.2	< 0.001	0.3	0.2-0.5	< 0.001
Sexual orientation (19,820)								
Heterosexual	76 (3.9)	2,813 (15.7)	1			1		
Homosexual/Gay/Lesbian	1,722 (87.8)	13,373(74.9)	4.3	3.4-5.4	< 0.001	2.7	2.0-3.7	< 0.001
Bisexual	164 (8.3)	1,672 (9.4)	3.4	2.6-4.4	< 0.001	1.9	1.4-2.7	< 0.001
Gender identity (19,820)								
Cisgender	1,889 (96.3)	17,423(97.6)	1					
Transgender	60 (3.0)	355 (2.0)	1.5	1.2-1.8	< 0.001			
Travestis	13 (0.7)	80 (0.4)	1.4	0.9-2.4	0.174			
Ethnicity/skin color (19,816)								
Pardo (Brown, i.e., mixed race)	650 (33.1)	5,436 (30.4)	1			1		

# 510 Table 3. Characteristics of PrEP users and factors associated with syphilis during follow-up, Brazil, 2018-2020.

White	1,043 (53.2)	9,964 (55.8)	0.9	0.8-0.98	0.02	0.8	0.7-0.9	< 0.001
Black	234 (11.9)	2,192 (12.3)	0.9	0.8-1.1	0.18	0.8	0.7-0.99	0.04
Yellow (i.e., Asian Brazilian)	25 (1.3)	199 (1.1)	1.04	0.8-1.5	0.83	1.0	0.6-1.5	0.97
Indigenous	9 (0.4)	64 (0.3)	1.15	0.5-2.1	0.67	1.2	0.6-2.4	0.56
Schooling level (19,817)								
8-11 years	419 (21.0)	4,171 (23.4)	1			1		
None/No formal education	1 (<0.1)	24 (0.1)	0.4	0.1-3.0	0.374			
1-3 years	6 (0.3)	77 (0.2)	0.8	0.4-1.7	0.550			
4-7 years	46 (2.3)	669 (3.7)	0.7	0.5-0.9	0.017			
12 years and over	1,490 (76.0)	12,914(72.3)	1.1	1.0-1.6	0.017			
Accepted something in exchange for sex in the last 6 months (19,819)								
Yes	252 (13.0)	1,484 (8.3)	1.5	1.3-1.7	< 0.001	1.6	1.3-1.9	< 0.001
No	1,710 (87.0)	16,373(91.7)	1			1		
History of syphilis in the 6 months before PrEP (19,820)								
Yes	318 (16.2)	1,275 (7.1)	2.2	2.0-2.5	< 0.001	2.2	1.9-2.5	< 0.001
No/Unknown	1,644 (83.8)	16,583(92.9)	1		1			
Condom use in the last 3 months <sup>¥</sup> (18,824)								

Never	408 (21.5)	4,240 (25.0)	1.3	1.1-1.5	< 0.001	1.2	1.1-1.5	0.01
Less than half of the time	397 (20.9)	2,453 (14.5)	2.1	1.8-2.4	< 0.001	1.7	1.5-2.0	< 0.001
Half of the time	281 (14.8)	1,830 (10.8)	2.0	1.7-2.3	< 0.001	1.7	1.5-2.1	< 0.001
More than half of the time	489 (25.7)	3,895 (23.0)	1.7	1.4-1.9	< 0.001	1.4	1.2-1.6	< 0.001
Always	324 (17.0)	4,507 (26.7)	1			1		
Sexual partners in the last 3 months <sup>¥</sup>								
Men	$18 \pm 230$ (4)	8 ± 36 (2)			< 0.001			< 0.001
Women	0.11±1.36(0)	$0.20 \pm 2.45(0)$			< 0.001			0.29
Trans women	0±0.05(0)	0.01±0.25 (0)			0.058			0.19
Trans men	0.01±0.13(0)	0.01±0.43(0)			0.006			
Travestis	0.01±0.35(0)	$0.01 \pm 0.54(0)$			0.944			
Alcohol use <sup>¥§</sup> (18,979)								
Yes	912 (47.0)	7,367 (43.0)	6.7	6.3-7.0	< 0.001			
No	1,009 (53.0)	9,691 (57.0)	1					
Use of injectable drugs <sup>¥</sup> (18,954)								
Yes	11 (0.6)	72 (0.4)	1.3	0.7-2.3	0.348			
No	1,913 (99.4)	16,958 (99.6)	1					
Uso of other psychoactive drugs								
Poppers	120 (6.1)	425 (2.4)	2.5	2.1-2.9	< 0.001	1.5	1.2-1.9	< 0.001

Cocaine	210 (11.0)	905 (5.1)	2.1	1.8-2.4	< 0.001	1.5	1.2-1.7	< 0.001
Crack	1 (<0.1)	26 (0.1)	0.4	0.1-2.8	0.597			
Marijuana	425 (22.0)	2,716 (15.0)	1.5	1.4-1.7	< 0.001	1.2	1.01-1.3	0.03
Club drugs (MDMA, GHB, ketamine, roofies, methamphetamine, and LSD)	216 (11.0)	1,237 (6.9)	1.7	1.5-1.9	<0.001			
Erection stimulants	220 (11.0)	1,126 (6.3)	1.8	1.6-2.1	< 0.001	1.1	0.96-1.3	0.14
Solvents	22 (1.1)	101 (0.6)	2.0	1.4-3.0	< 0.001			

511 \* RR: Relative Risk \*\* Mean ± Standard Deviation (Median); \*\*\* Chi-square test;

512 ¥ Data from the last follow-up appointment <sup>\$</sup> 5 doses or more in two hours; <sup>%</sup> Fischer exact test .<sup>#</sup> aOR: Adjusted Odds Ratio <sup>##</sup> 95%CI: 95% Confidence Interval.

513 Akaike Information Criterion (AIC) = 11.367; pseudoR<sup>2</sup> = 0.157.